ClinicalTrials.Veeva

Menu

Prospective Quality Improvement Project for High-Risk Diabetes Patients

T

Taipei Medical University

Status

Enrolling

Conditions

Quality of Life
Latent Tuberculosis Infection
Diabetes Mellitus
Continuous Glucose Monitoring

Treatments

Behavioral: enhanced interactive education

Study type

Interventional

Funder types

Other

Identifiers

NCT06472609
N202105025

Details and patient eligibility

About

Diabetes is the most important comorbidity of tuberculosis patients in Taiwan, and 1/4 of tuberculosis patients also It is a diabetic patient, and the treatment of latent tuberculosis infection is currently an important policy of the Taiwan Disease Control Agency One, because babies are prone to encounter difficulties in the early stages, because of the spread of Australian patients in the community, The Department of Disease Control encourages patients with diabetes to receive screening and treatment for latent tuberculosis infection.

Full description

Diabetes mellitus is the most prevalent comorbiditiy for patients with active tuberculosis in Taiwan. More than one fourth of the patients with incident tuberculosis has diabetes mellitus. The latent tuberculosis infection treatment is recommended by the Centers of Disease Control (CDC) of Taiwan to halt the transmission of tuberculosis in the community. Considering a relatively long delay in diagnosis of tuberculosis in clinical practice, eliminate the dormant tuberculosis germs a the stage of latent infection is the most cost-effective strategy to avoid tuberculosis transmission. The population with diabetes mellitus and inadequate blood sugar control are at increased risk of latent tuberculosis infection and activation and are encouraged to undergo latent tuberculosis screening and treatment. However, the anti-tuberculosis agents could have significant drug-drug interaction with the drugs used for diabetes mellitus control. The extent of its impact on blood sugar is still unclear. We aim to investigate the fluctuation of blood sugar during latent tuberculosis treatment with continuous subcutaneous sugar monitoring device to evaluate the possible associated risk of hyperglycemia or hypoglycemia to enhance treatment safety. Inadequate blood sugar control is the root for immune dysfunction and render the patients vulnerable to infectious diseases. Hence, improvement in the blood sugar control not only leads to a better immune function to avoid tuberculosis infection but also reduce the risk of progression for cardiovascular and renal disorder. The present study proposed a protocol of 12-week aggressive blood sugar control and education program using phone call to improve the blood sugar control and life quality. Furthermore, to evaluate the efficacy of anti-tuberculosis treatment for latent tuberculosis, we propose to evaluate the mycobacteria-specific antigen immune response by using the interferon-gamma releasing assay before and after anti-tuberculosis treatment.

Enrollment

300 estimated patients

Sex

All

Ages

20 to 99 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Diabetic patients had a record of glycated hemoglobin (HbA1C%) greater than 9% in the past year.

Exclusion criteria

  • Be younger than 20 years old.
  • Unconsciousness or severe dementia, unable to conduct quality of life questionnaire assessment.

Trial design

Primary purpose

Prevention

Allocation

N/A

Interventional model

Sequential Assignment

Masking

None (Open label)

300 participants in 1 patient group

interactive group
Experimental group
Description:
diabetes, enhanced interactive education program through weekly phone call for 12 weeks
Treatment:
Behavioral: enhanced interactive education

Trial contacts and locations

1

Loading...

Central trial contact

Jing-En Dai; Chih-Hsin Lee

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems